Our Vaccines

Science

Vaxxilon was founded to develop synthetic carbohydrate vaccines. These vaccines are comprised of oligosaccharides (small fragments of naturally occurring carbohydrates) and the novel immune stimulator, alpha galactosylceramide. Two fundamental insights are the basis of this science:

Vaccine component

Advantages

ANTIGEN: Small, synthesized carbohydrate fragments which are the vaccine antigens can induce equivalent immunological response and memory. They replicate the natural structure of bacterial capsular polysaccharides.

Synthetic antigens are faster and less expensive to discover, develop, and manufacture. They could allow for lower doses, lead to protein sparing, and enable higher valency vaccines.

CARRIER: α-galactosylceramide (α-GSL) can replace carrier proteins and adjuvants used in currently available conjugate vaccines.

Fully synthetic vaccines which include a synthetic antigen and α-GSL are stable at room temperature. They could reduce the need for cumbersome cold chain distribution. The immunological mechanism of action may reduce the number of booster shots or allow for non-injectable administrations, easing the burden on the patients, parents, and health care providers around the world.

Learn more: How Vaxxilon uses rational design to create Novel Antigens

Pipeline

Through the rationale design of synthetic carbohydrate vaccines, Vaxxilon aims to improve existing vaccines and create new ones faster and less expensively with benefits to patients, parents, and health care providers around the world. We are advancing several vaccine candidates and considering new projects to initiate.

Bacteria	Serotype	Vaccine Type	Discovery
Streptococcus pneumoniae	3	Semi-synthetic	.
Haemophilus influenzae type B	n/a	Semi-synthetic	.
Streptococcus pneumoniae	multiple, undisclosed	Semi-synthetic	.
Streptococcus pneumoniae	not disclosed	Fully-synthetic	.
Klebsiella pneumoniae	multiple	Semi-synthetic	.
2 additional targets	undisclosed		.

Publications

Semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 5
Author: Marilda P. Lisboa, Naeem Khan, Christopher Martin, Fei-Fei Xu, Katrin Reppe, Andreas Geissner, Subramanian Govindan, Martin Witzenrath, Claney L. Pereira, and Peter H. Seeberger
Journal: PNAS - Proceedings of the Natural Academy of Sciences of the United States of America , Published Date: October 2, 2017

A Streptococcus pneumoniae type 2 oligosaccharide glycoconjugate elicits opsonic antibodies and is protective in an animal model of invasive pneumococcal disease
Author: Madhu Emmadi, Naeem Khan, Lennart Lykke, Katrin Reppe, Sharavathi G. Parameswarappa, Marilda P Lisboa, Sandra-Maria Wienhold, Martin Witzenrath, Claney L Pereira, and Peter H Seeberger
Journal: Journal of the American Chemical Society , Published Date: September 25, 2017

A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant Klebsiella pneumoniae
Author: Seeberger PH, Pereira CL, Khan N, Xiao G, Diago-Navarro E, Reppe K, Optiz B, Fries B, Witzenrath M
Journal: Angewandte Chemie International Edition , Published Date: August 16, 2017

A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine
Author: Schumann B, Hahm HS, Parameswarappa SG, Reppe K, Wahlbrink A, Govindan S, Kaplonek P, Pirofski LA, Witzenrath M, Anish C, Pereira CL, Seeberger PH.
Journal: Sci Transl Med. , Volume: 9 , Issue: 380 , Pages: eaaf5347 , Published Date: March 8, 2017

Total synthesis of a Streptococcus pneumoniae serotype 12F CPS repeating unit hexasaccharide
Author: Seeberger PH, Pereira CL, Govindan S.
Journal: Beilstein J Org Chem. , Volume: 13 , Pages: 164-173 , Published Date: January 25, 2017

A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection.
Author: Parameswarappa SG, Reppe K, Geissner A, Ménová P, Govindan S, Calow AD, Wahlbrink A, Weishaupt MW, Monnanda BP, Bell RL, Pirofski LA, Suttorp N, Sander LE, Witzenrath M, Pereira CL, Anish C, Seeberger PH.
Journal: Cell Chem Biol. , Volume: 23 , Issue: 11 , Pages: 1407-1416 , Published Date: November 17, 2016

A semisynthetic carbohydrate-lipid vaccine that protects against S. pneumoniae in mice
Author: Cavallari M, Stallforth P, Kalinichenko A, Rathwell DC, Gronewold TM, Adibekian A, Mori L, Landmann R, Seeberger PH, De Libero G.
Journal: Nat Chem Biol. , Volume: 10 , Issue: 11 , Pages: 950-956 , Published Date: October 5, 2014

Chemical biology approaches to designing defined carbohydrate vaccines
Author: Anish C, Schumann B, Pereira CL, Seeberger PH.
Journal: Chem Biol. , Volume: 21 , Issue: 1 , Pages: 38-50 , Published Date: January 16, 2014

Basel Area Vaxxilon AG Christoph Merian-Ring 11, 4153 Reinach, Switzerland

Berlin Area (Adlershof) Vaxxilon Deutschland GmbH Magnusstraße 11, 12489 Berlin, Germany

Click here to Email us